Parabilis Medicines moved to upsize its IPO plans, signaling intent to pursue a potentially record-setting $637 million fundraising. The company’s plans arrive amid sustained demand in biotech public listings even as markets focus on cash runway and near-term development catalysts. The move also underscores the ongoing appetite for oncology-focused platforms that can demonstrate pipeline credibility and commercial positioning. For investors, an upsized IPO can be a test of how quickly underwritten deal demand translates into durable valuation support in the public biotech sector. Parabilis’ update follows recent sector-wide IPO momentum, with investors increasingly looking for differentiated late-stage exposure or clear regulatory timelines to justify entry pricing.